[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adenomatous-polyps\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adenomatous-polyps":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,58,92,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100617125","recurrence-after-gastric-and-intestinal-polyp-resection-100617125",false,"NCT07314554","Recurrence After Gastric and Intestinal Polyp Resection","Recurrence Rate and Risk Factors After Endoscopic Resection of Gastric and Intestinal Polyps: A Retrospective and Prospective Cohort Study","RAGIP","Inclusion Criteria:\n\n* Age 18 years or older\n* First-time endoscopic examination (gastroscopy or colonoscopy) at the study center\n* Pathologically confirmed polyp of any type (adenomatous, hyperplastic, inflammatory, fundic gland polyp, hamartomatous, serrated lesion)\n* Complete endoscopic resection performed (including EMR, ESD, snare polypectomy, hot biopsy forceps, or argon plasma coagulation)\n* Negative resection margins or complete resection assessed by pathology\n* At least one follow-up endoscopic examination completed (for retrospective cohort) or willingness to complete follow-up (for prospective cohort)\n* Complete baseline clinical data available\n\nExclusion Criteria:\n\n* Hereditary polyposis syndromes (familial adenomatous polyposis, Lynch syndrome, Peutz-Jeghers syndrome, juvenile polyposis syndrome)\n* Inflammatory bowel disease (ulcerative colitis or Crohn's disease)\n* Previous history of gastric or colorectal cancer\n* Cancer detected at initial resection (stage T1b or higher)\n* Non-polyp pathology (e.g., submucosal tumors, normal mucosa)\n* Incomplete resection with positive margins that were not re-treated\n* Lost to follow-up with no available surveillance data (for retrospective cohort)\n* Pregnancy at time of enrollment\n* Inability or unwillingness to provide informed consent (for prospective cohort)","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","3 Years","OBSERVATIONAL","This is a retrospective and prospective cohort study designed to evaluate the recurrence rate and identify risk factors after endoscopic resection of gastric and intestinal polyps.\n\nBACKGROUND: Gastric and intestinal polyps are common digestive diseases with potential for malignant transformation. Although endoscopic resection is the standard treatment, recurrence rates range from 10-50%, and the mechanisms and risk factors remain unclear.\n\nOBJECTIVES:\n\nPrimary: To assess short-term (1-year) and long-term (3-year) recurrence rates after endoscopic polyp resection Secondary: To identify independent risk factors and develop a recurrence risk prediction model\n\nDESIGN: Mixed retrospective-prospective cohort study\n\n* Retrospective cohort: Patients who underwent polyp resection from 2021-2022, with follow-up data through 2024\n* Prospective cohort: Patients enrolled from 2024-2025, with standardized follow-up through 2028\n\nSETTING: Single tertiary referral center with \\>10,000 endoscopic polyp resections performed since 2021\n\nPARTICIPANTS: Approximately 1,600-1,800 adult patients (≥18 years) who underwent complete endoscopic resection of gastric or intestinal polyps\n\nFOLLOW-UP:\n\n* Short-term: 1 year post-resection (±2 months)\n* Long-term: 3 years post-resection (±3 months)\n\nMAIN OUTCOME: Recurrence rate defined as new polyp detection at original or different sites during endoscopic surveillance\n\nPOTENTIAL RISK FACTORS: Patient demographics, polyp characteristics (size, number, location, pathology), resection method, Helicobacter pylori status, lifestyle factors, and medication use\n\nEXPECTED IMPACT: Results will inform personalized surveillance strategies and optimize resource allocation for post-polypectomy follow-up.",[26,27,28,29,30,31,32],"Gastric Polyps","Intestinal Polyps","Colon Polyps","Colorectal Polyps","Adenomatous Polyps","Gastric Adenoma and Early Gastric Cancer","Colorectal Adenoma",[34,35,36,37,38,39,40,41,42,43,44],"Polyp recurrence","Endoscopic resection","Polypectomy","Endoscopic mucosal resection","Endoscopic submucosal dissection","Risk factors","Surveillance","Follow-up","Adenoma","Gastric polyp","Colorectal polyp","NOT_YET_RECRUITING","2026-06-07",{"date":48,"type":49},"2026-06-09","ACTUAL",{"date":51,"type":21},"2026-07-26",{"date":53,"type":21},"2029-02-25",{"name":55,"class":56},"LanZhou University","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":57},"100589956","linked-color-imaging-versus-indigo-carmine-pump-spraying-on-the-colorectal-adenoma-detection-rate-100589956","NCT06961149","Linked-Color Imaging Versus Indigo Carmine Pump Spraying on the Colorectal Adenoma Detection Rate","Linked-Color Imaging Versus Indigo Carmine Pump Spraying on the Colorectal Adenoma Detection Rate: a Prospective , Randomized Controlled, Non-inferiority Study","Inclusion Criteria:\n\n1. Age between 45 and 85 years\n2. Patients with a history of colorectal adenoma\n3. Patients whose first-degree relatives have a history of colorectal cancer or colorectal adenoma\n4. Patients with gastrointestinal symptoms (abdominal pain, bloody stool, chronic diarrhea or constipation, Unexplained anemia or weight loss;\n5. Patients with positive Fecal Immunochemical Test\n\nExclusion Criteria:\n\n1. Patients with pregnancy, inflammatory bowel disease, familial adenomatosis polyposis, suspected CRC; intestinal obstruction, coagulopathy\n2. Patients with aspirin, clopidogrel or other anticoagulants\u002F antiplatelet drugs intake within 7 days\n3. Patents previous colorectal resection\n4. Patients with failed cecal intubation\n5. Patients with inadequate bowel preparation quality (BBPS≤5)\n6. Patients who refuse to participate or to provide informed consent","45 Years","85 Years",{"count":68,"type":21},352,"INTERVENTIONAL",[71],"NA","Detection and removal of polyps during colonoscopy is crucial for the prevention of colorectal cancer. Indigo carmine spraying up to the colonic mucosa could probably increase the adenoma detection rate, but considering the long withdrawal time of the endoscope and the resulting increase in time and cost. Linked-color imaging (LCI) is a newly developed image-enhanced endoscopy technology. It relies on wave length optimization of three colors (red, green, and blue) to make the lesions appear fuller. LCI improves the visibility of colorectal adenomas and polyps and may increase the detection rate of lesions. In order to explore the clinical application value of Linked-color imaging endoscopy, we performed a prospective, randomized controlled trial to compare adenoma detection rate of Linked-color imaging endoscopy and indigo carmine chromoendoscopy.",[74,30,75,76,77],"Colonic Polyps","Adenoma Detection Rate","Chromoendoscopy","Colorectal Neoplasms",[75,79,76,80,81],"Linked-color imaging","Colonoscopy","Indigo Carmine","RECRUITING","2025-05-05",{"date":85,"type":49},"2025-05-07",{"date":87,"type":49},"2025-04-08",{"date":89,"type":21},"2026-04-01",{"name":91,"class":56},"Shandong University",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":69,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":57},"100425160","a-comparison-of-the-resection-rate-for-hot-and-cold-snare-polypectomy-of-colorectal-polyps-10-15-mm-100425160","NCT04816292","A Comparison of the Resection Rate for Hot and Cold Snare Polypectomy of Colorectal Polyps (10-15 Mm)","A Comparison of the Resection Rate for Hot and Cold Snare Polypectomy of Colorectal Polyps (10-15 Mm) - a Randomized Controlled Trial (COLDSNAP-2)","COLDSNAP-2","Inclusion Criteria:\n\n* Indication for colonoscopy\n* at least 1 adenomatous polyp 10-15 mm\n* provided written informed consent\n\nExclusion Criteria:\n\n* American Society of Anaesthesiologists class IV or higher\n* florid inflammatory bowel disease\n* emergency indication for colonoscopy\n* haemorrhagic diathesis\n* continued dual antiplatelet therapy\n* continued anticoagulant therapy","80 Years",{"count":102,"type":21},850,[71],"Colorectal cancer (CRC) has become the third most common malignant tumor and is the second leading cause of cancer related deaths worldwide. Adenomatous polyps of the colon are possible precursor lesions for CRC. Screening for CRC has been shown effective in preventing CRC and related deaths, especially colonoscopy and resection of adenomatous polyps. Currently, for intermediate sized polyps 5 - 19 mm hot snare polypectomy (HSP) with the use of electrocautery is conventionally used, causing relevant adverse events including haemorrhage and postpolypectomy coagulation syndrome, but is safe regarding complete resection of the polyp due to burning effect on residual tissue. On the other hand, cold snare polypectomy (CSP) has grown popularity. Absence of electrocautery makes it technically easier and most important reduces adverse events. CSP is recommended as the preferred technique for polyps \\\u003C5 mm by the European Society of Gastrointestinal Endoscopy (ESGE) guidelines. In literature, there is one multicenter trial from Japan recommending CSP for polyps 4-9 mm (average polyp size 5,4 mm) and only a few case studies for polyps 10-15 mm with inconsistent results, especially regarding the complete resection and pathological evaluation of the specimen.\n\nIn this randomized controlled trial, the investigators want to compare the complete resection rates of small and intermediate sized colorectal polyps 10-15 mm with CSP and HSP.",[30],"2024-11-07",{"date":108,"type":49},"2024-11-12",{"date":110,"type":49},"2024-11-05",{"date":112,"type":21},"2026-03",{"name":114,"class":56},"Technical University of Munich",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":122,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100533038","multi-omics-study-for-early-detection-of-colorectal-cancer-moed-crc-100533038","NCT06220617","Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)","Multi-omics Study for Early Detection of Colorectal Cancer Based on Liquid Biopsy Technology","Inclusion Criteria for Case Arm:\n\n1. Aged over 18 years.\n2. Participants confirmed with colorectal adenocarcinoma or advanced adenoma through colonoscopy and pathological examination.\n3. Provision of informed consent prior to any study specific procedures, sampling, and analyses.\n\nInclusion Criteria for Control Arm:\n\n1. Individuals of \"General risk arm\" should meet all the following criteria:\n\n   1. No history of colorectal adenomas or sessile serrated polyps.\n   2. No history of inflammatory bowel disease (8-10 years ).\n   3. No family history (first-degree relatives) of colorectal cancer.\n2. Individuals of \"High-risk arm\" should meet at least one of the following criteria:\n\n   1. Asia-Pacific Colorectal Screening (APC) score ≥ 3.\n   2. Family history (first-degree relatives) of colorectal cancer.\n   3. History of positive fecal occult blood test.\n   4. Any 2 of the following: chronic diarrhea, chronic constipation, mucous bloody stools, history of psychological stimulation, history of chronic appendicitis or appendectomy, history of chronic biliary disease or cholecystectomy.\n   5. Individuals with inflammatory bowel disease.\n3. All participants must be confirmed not to have colorectal malignancy or advanced adenomas through colonoscopy.\n4. Provision of informed consent prior to any study specific procedures, sampling, and analyses.\n\nExclusion Criteria:\n\n1. History of other malignant tumors (excluding non-melanoma skin cancer).\n2. Prior or related treatments previously (including colorectal cancer or advanced adenoma surgery, endoscopic treatment, chemotherapy, targeted therapy, immunotherapy, radiation, neoadjuvant therapy, etc.).\n3. Patients with hereditary colorectal diseases (including Lynch syndrome, familial CRC type X (FCCX), familial adenomatous polyposis (FAP), MUTHY-associated polyposis (MAP), Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS), serrated polyposis syndrome (SPS), etc.).\n4. Usage of anti-tumor drugs such as methotrexate, cyclophosphamide, mercaptopurine, and bendamustine for other diseases within 30 days before blood collection.\n5. Prior blood transfusion (including blood components) within the past 2 weeks.\n6. Prior organ transplantation, bone marrow transplantation, or stem cell transplantation.\n7. Pregnancy women.\n8. Prior or current anti-infection treatment within 14 days before blood collection.\n9. Inability to comply with study procedures such as blood collection and related examinations.\n10. Deemed unsuitable for participation in the clinical trial by the investigator.",true,{"count":124,"type":21},3600,"The primary objective of the study is to screen multi-omics markers in blood samples and construct a prediction model for CRC based on liquid biopsy, and we will further optimize the prediction model by validating its clinical performance externally.",[127,30,42,128],"Colorectal Cancer","Advanced Adenoma",[127,77,30,42,130],"Advanced adenoma","2024-01-28",{"date":133,"type":49},"2024-01-30",{"date":135,"type":49},"2024-01-11",{"date":137,"type":21},"2027-06-30",{"name":139,"class":56},"Zhejiang University",6]